Skip to content
2000
Volume 22, Issue 5
  • ISSN: 1567-2050
  • E-ISSN: 1875-5828

Abstract

Introduction

The aim of this study was to assess the relationship between serum biomarkers of vascular dysfunction and neuropsychological performance in Alzheimer’s disease (AD) patients.

Materials and Methods

In this cross-sectional observational study, outpatients with AD who were referred to the Neuropsychiatry Clinic of the Eginition Hospital in Athens from January 2006 to December 2006 were consecutively enrolled. All the participants underwent a neuropsychological assessment.

The serum concentrations of Apolipoprotein A1 (ApoA1), Vascular Cell Adhesion Molecule 1 (VCAM-1), Intercellular Adhesion Molecule 1 (ICAM-1), Lipoprotein-A (LpA), and C-Reactive Protein (CR-P) were determined.

Results

Fifty-six AD patients were enrolled. ApoA1 was correlated with Mini Mental State Examination (MMSE) and AD Cooperative Study-Activities of Daily Living (ADCS-ADL). Combined biomarkers were correlated with MMSE, Neuropsychiatry Inventory, Clinical Dementia Rating Scale, and ADCS-ADL.

Discussion

Our study highlights the association between serum biomarkers of vascular dysfunction-specifically ApoA1, VCAM-1, ICAM-1, LpA, and CRP-and the cognitive and behavioral features of Alzheimer’s Disease.

Conclusion

These findings suggest that assessing vascular biomarkers may offer valuable insights into the pathophysiological mechanisms underlying cognitive and behavioral decline in AD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/car/10.2174/0115672050384313250612045355
2025-06-25
2025-11-07

  • From This Site

    /content/journals/car/10.2174/0115672050384313250612045355
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Europe, A. Dementia in Europe Yearbook 2019: Estimating the prevalence of dementia in Europe. Alzheimer EuropeLuxembourg2020
     [Google Scholar]
  2. LaneC.A. HardyJ. SchottJ.M. Alzheimer’s disease.Eur. J. Neurol.2018251597010.1111/ene.1343928872215
     [Google Scholar]
  3. LucaM. LucaA. CalandraC. The role of oxidative damage in the pathogenesis and progression of Alzheimer’s disease and vascular dementia.Oxid. Med. Cell. Longev.201520151810.1155/2015/50467826301043
     [Google Scholar]
  4. LucaA. CalandraC. LucaM. Molecular bases of Alzheimer’s disease and neurodegeneration: The role of neuroglia.Aging Dis.2018961134115210.14336/AD.2018.020130574424
     [Google Scholar]
  5. De StrooperB. KarranE. The cellular phase of Alzheimer’s disease.Cell2016164460361510.1016/j.cell.2015.12.05626871627
     [Google Scholar]
  6. RoherA.E. EshC. KokjohnT.A. KalbackW. LuehrsD.C. SewardJ.D. SueL.I. BeachT.G. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease.Arterioscler. Thromb. Vasc. Biol.200323112055206210.1161/01.ATV.0000095973.42032.4414512367
     [Google Scholar]
  7. ArvanitakisZ. CapuanoA.W. LeurgansS.E. BennettD.A. SchneiderJ.A. Relation of cerebral vessel disease to Alzheimer’s disease dementia and cognitive function in elderly people: A cross-sectional study.Lancet Neurol.201615993494310.1016/S1474‑4422(16)30029‑127312738
     [Google Scholar]
  8. HofmanA. OttA. BretelerM.M.B. BotsM.L. SlooterA.J.C. van HarskampF. van DuijnC.N. Van BroeckhovenC. GrobbeeD.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam study.Lancet1997349904615115410.1016/S0140‑6736(96)09328‑29111537
     [Google Scholar]
  9. KullerL.H. LopezO.L. MackeyR.H. RosanoC. EdmundowiczD. BeckerJ.T. NewmanA.B. Subclinical cardiovascular disease and death, dementia, and coronary heart disease in patients 80+ years.J. Am. Coll. Cardiol.20166791013102210.1016/j.jacc.2015.12.03426940919
     [Google Scholar]
  10. XieB. ShiX. XingY. TangY. Association between atherosclerosis and Alzheimer’s disease: A systematic review and meta-analysis.Brain Behav.2020104e0160110.1002/brb3.160132162494
     [Google Scholar]
  11. ChenJ. DaiA.X. TangH.L. LuC.H. LiuH.X. HouT. LuZ.J. KongN. PengX.Y. LinK.X. ZhengZ.D. XuS.L. YingX.F. JiX.Y. PanH. WuJ. ZengX. WeiN.L. Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer’s disease.Front. Immunol.202313109740910.3389/fimmu.2022.109740936685605
     [Google Scholar]
  12. MerchedA. XiaY. VisvikisS. SerotJ.M. SiestG. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease.Neurobiol. Aging2000211273010.1016/S0197‑4580(99)00103‑710794845
     [Google Scholar]
  13. PillaiJ.A. BenaJ. BekrisL. KodurN. KasumovT. LeverenzJ.B. KashyapS.R. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease.Alzheimers Res. Ther.20231515410.1186/s13195‑023‑01203‑y36927447
     [Google Scholar]
  14. Diagnostic and Statistical Manual of Mental Disorders.American Psychiatric Association: 4th Edition Revised, Washington DC2002
     [Google Scholar]
  15. PolitisA. OlgiatiP. MalitasP. AlbaniD. SignoriniA. PolitoL. De MauroS. ZisakiA. PiperiC. StamouliE. MailisA. BatelliS. ForloniG. De RonchiD. KalofoutisA. LiappasI. SerrettiA. Vitamin B12 levels in Alzheimer’s disease: Association with clinical features and cytokine production.J. Alzheimers Dis.201019248148810.3233/JAD‑2010‑125220110595
     [Google Scholar]
  16. FountoulakisK TsolakiM ChantziH KazisA. Mini mental state examination (MMSE): A validation study in Greece.Am. J. Alzheimers Dis. Other. Demen.200015634234510.1177/153331750001500604
     [Google Scholar]
  17. PolitisA.M. MayerL.S. PassaM. MaillisA. LyketsosC.G. Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer’s disease: A study of disturbing behaviors among referrals to a memory clinic.Int. J. Geriatr. Psychiatry200419320320810.1002/gps.104515027034
     [Google Scholar]
  18. AlexopoulosG.S. AbramsR.C. YoungR.C. ShamoianC.A. Cornell scale for depression in dementia.Biol. Psychiatry198823327128410.1016/0006‑3223(88)90038‑83337862
     [Google Scholar]
  19. GalaskoD. BennettD. SanoM. ErnestoC. ThomasR. GrundmanM. FerrisS. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s disease cooperative study.Alzheimer Dis. Assoc. Disord.199711Suppl. 2S33S3910.1097/00002093‑199700112‑000059236950
     [Google Scholar]
  20. MorrisJ.C. The Clinical Dementia Rating (CDR): Current version and scoring rules.Neurology199343112412241410.1212/WNL.43.11.2412‑a8232972
     [Google Scholar]
  21. MarcovinaS.M. AlbersJ.J. HendersonL.O. HannonW.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B.Clin. Chem.19913710 Pt 1167616821914164
     [Google Scholar]
  22. TsujisakiM. ImaiK. HirataH. HanzawaY. MasuyaJ. NakanoT. SugiyamaT. MatsuiM. HinodaY. YachiA. Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases.Clin. Exp. Immunol.20088513810.1111/j.1365‑2249.1991.tb05673.x1712683
     [Google Scholar]
  23. UrakamiK. Wada-IsoeK. WakutaniY. IkedaK. JiY. YamagataK. KowaH. OkadaA. AdachiY. NakashimaK. Lipoprotein(a) phenotypes in patients with vascular dementia.Dement. Geriatr. Cogn. Disord.200011313513810.1159/00001722610765043
     [Google Scholar]
  24. von KänelR. MillsP.J. MausbachB.T. DimsdaleJ.E. PattersonT.L. ZieglerM.G. Ancoli-IsraelS. AllisonM. ChattillionE.A. GrantI. Effect of Alzheimer caregiving on circulating levels of C-reactive protein and other biomarkers relevant to cardiovascular disease risk: A longitudinal study.Gerontology201258435436510.1159/00033421922133914
     [Google Scholar]
  25. AcockA.C. A gentle introduction to Stata.Stata PressPhiladelphia, PA2nd2008
     [Google Scholar]
  26. ZhangH. YanC. ZhouS. GuanJ. ZhangJ. Combined cause inference: Definition, model and performance.Inf. Sci.202157443144310.1016/j.ins.2021.06.004
     [Google Scholar]
  27. EndresK. Apolipoprotein A1, the neglected relative of Apolipoprotein E and its potential role in Alzheimer’s disease.Neural Regen. Res.202116112141214810.4103/1673‑5374.31066933818485
     [Google Scholar]
  28. HampelH. HuY. CummingsJ. MattkeS. IwatsuboT. NakamuraA. VellasB. O’BryantS. ShawL.M. ChoM. BatrlaR. VergalloA. BlennowK. DageJ. SchindlerS.E. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape.Neuron2023111182781279910.1016/j.neuron.2023.05.01737295421
     [Google Scholar]
  29. PetersenM.E. O’BryantS.E. Blood-based biomarkers for Down syndrome and Alzheimer’s disease: A systematic review.Dev. Neurobiol.201979769971010.1002/dneu.2271431389185
     [Google Scholar]
  30. HelbecqueN. CodronV. CottelD. AmouyelP. An apolipoprotein A-I gene promoter polymorphism associated with cognitive decline, but not with Alzheimer’s disease.Dement. Geriatr. Cogn. Disord.20082529710210.1159/00011217618073484
     [Google Scholar]
  31. SaczynskiJ.S. WhiteL. PeilaR.L. RodriguezB.L. LaunerL.J. The relation between apolipoprotein A-I and dementia: The Honolulu-Asia aging study.Am. J. Epidemiol.2007165998599210.1093/aje/kwm02717298957
     [Google Scholar]
  32. ReynoldsC.A. GatzM. PrinceJ.A. BergS. PedersenN.L. Serum lipid levels and cognitive change in late life.J. Am. Geriatr. Soc.201058350150910.1111/j.1532‑5415.2010.02739.x20398119
     [Google Scholar]
  33. TynkkynenJ. HernesniemiJ.A. LaatikainenT. HavulinnaA.S. SundvallJ. LeiviskäJ. SaloP. SalomaaV. Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer’s disease: The National Finnish population study (FINRISK).Age2016385-646547310.1007/s11357‑016‑9950‑x27663235
     [Google Scholar]
  34. WangJ. XuL. ChenX. WuJ. ChenY. FengZ. DongL. YaoD. CaiQ. JianW. LiH. DuanM. WangZ. Correlation analysis of ApoB, ApoA1, and ApoB/ApoA1 with cortical morphology in patients with memory complaints.J. Alzheimers Dis.202410141137115010.3233/JAD‑23086339302359
     [Google Scholar]
  35. SlotR.E.R. Van HartenA.C. KesterM.I. JongbloedW. BouwmanF.H. TeunissenC.E. ScheltensP. VeerhuisR. van der FlierW.M. Apolipoprotein A1 in cerebrospinal fluid and plasma and progression to Alzheimer’s disease in non-demented elderly.J. Alzheimers Dis.201756268769710.3233/JAD‑15106828035918
     [Google Scholar]
  36. KawanoM. KawakamiM. OtsukaM. YashimaH. YaginumaT. UekiA. Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer’s disease.Clin. Chim. Acta1995239220921110.1016/0009‑8981(95)06115‑T8542660
     [Google Scholar]
  37. KuriyamaM. TakahashiK. YamanoT. HokezuY. TogoS. OsameM. IgakuraT. Low levels of serum apolipoprotein AI and AII in senile dementia.Jpn. J. Psychiatry Neurol.19944835895937891423
     [Google Scholar]
  38. FrondeliusK. BorgM. EricsonU. BornéY. MelanderO. SonestedtE. Lifestyle and dietary determinants of serum apolipoprotein A1 and apolipoprotein B concentrations: Cross-sectional analyses within a Swedish cohort of 24,984 individuals.Nutrients20179321110.3390/nu903021128264492
     [Google Scholar]
  39. ZhangX. GengT. LiN. WuL. WangY. ZhengD. GuoB. WangB. Associations of lipids and lipid-lowering drugs with risk of vascular dementia: A Mendelian randomization study.Nutrients20221516910.3390/nu1501006936615727
     [Google Scholar]
  40. DrakeJ.D. ChambersA.B. OttB.R. DaielloL.A. Peripheral markers of vascular endothelial dysfunction show independent but additive relationships with brain-based biomarkers in association with functional impairment in Alzheimer’s disease.J. Alzheimers Dis.20218041553156510.3233/JAD‑20075933720880
     [Google Scholar]
  41. YouyouZ. RuiruiJ. HuiW. ZhaoyangL. Association between lipoprotein(a) and ischemic stroke: Fibrinogen as a mediator.J. Neurol. Sci.202345212073812073810.1016/j.jns.2023.12073837517272
     [Google Scholar]
  42. KunutsorS.K. KhanH. NyyssönenK. LaukkanenJ.A. Is lipoprotein (a) protective of dementia?Eur. J. Epidemiol.201631111149115210.1007/s10654‑016‑0184‑027412033
     [Google Scholar]
  43. RöhrF. BucholtzN. ToepferS. NormanK. SpiraD. Steinhagen-ThiessenE. LillC.M. BertramL. DemuthI. BuchmannN. DüzelS. Relationship between Lipoprotein (a) and cognitive function – Results from the Berlin aging study II.Sci. Rep.20201011063610.1038/s41598‑020‑66783‑332606300
     [Google Scholar]
  44. EmanueleE. CarlinM.V. D’AngeloA. PerosE. BaraleF. GeroldiD. PolitiP. Elevated plasma levels of lipoprotein(a) in psychiatric patients: A possible contribution to increased vascular risk.Eur. Psychiatry200621212913310.1016/j.eurpsy.2004.10.00216516110
     [Google Scholar]
  45. BahorikA.L. HoangT.D. JacobsD.R. LevineD.A. YaffeK. Association of changes in C-reactive protein level trajectories through early adulthood with cognitive function at midlife: The CARDIA study.Neurology20241032e20952610.1212/WNL.000000000020952638959452
     [Google Scholar]
  46. GongC. WeiD. WangY. MaJ. YuanC. ZhangW. YuG. ZhaoY. A meta-analysis of C-reactive protein in patients with Alzheimer’s disease.Am. J. Alzheimers Dis. Other Demen.201631319420010.1177/153331751560208726340961
     [Google Scholar]
  47. SimpsonA.J. Wyman-ChickK.A. DanielM.S. Neuropsychological and clinical indicators of Lewy body and Alzheimer’s pathology.J. Alzheimers Dis. Rep.202592542482324130438610.1177/2542482324130438640034524
     [Google Scholar]
  48. EmamzadehF.N. AllsopD. α-synuclein interacts with lipoproteins in plasma.J. Mol. Neurosci.201763216517210.1007/s12031‑017‑0967‑028887769
     [Google Scholar]
  49. YuY. ShenH. QinQ. WangJ. NieY. WenL. TangY. QuM. The investigation of peripheral inflammatory and oxidative stress biomarkers in dementia with Lewy Bodies, compared with Alzheimer’s Disease, and mild cognitive impairment.Neuroscience202556820921810.1016/j.neuroscience.2024.12.05739800047
     [Google Scholar]
/content/journals/car/10.2174/0115672050384313250612045355
Loading
Serum Biomarkers of Vascular Dysfunction, Neuropsychiatric Symptoms, and Clinical Severity of Alzheimer’s Disease: A Cross-sectional Study
Curr Alzheimer Res 22, 396 (2025); https://doi.org/10.2174/0115672050384313250612045355
/content/journals/car/10.2174/0115672050384313250612045355
/content/journals/car/10.2174/0115672050384313250612045355
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Alzheimer’s disease; behavioral decline; biomarkers; neuropsychological performances; serum; vascular dysfunction

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test